Inoue S - Search Results

1

Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.

Ide H, Inoue S, Mizushima T, Jiang G, Chuang KH, Oya M, Miyamoto H. Ide H, et al. Among authors: inoue s. Mol Cancer Ther. 2018 Jul;17(7):1566-1574. doi: 10.1158/1535-7163.MCT-17-1061. Epub 2018 May 2. Mol Cancer Ther. 2018. PMID: 29720561

2

Increased expression of estrogen-related receptor alpha (ERRalpha) is a negative prognostic predictor in human prostate cancer.

Fujimura T, Takahashi S, Urano T, Kumagai J, Ogushi T, Horie-Inoue K, Ouchi Y, Kitamura T, Muramatsu M, Inoue S. Fujimura T, et al. Among authors: inoue s. Int J Cancer. 2007 Jun 1;120(11):2325-30. doi: 10.1002/ijc.22363. Int J Cancer. 2007. PMID: 17294452 Free article.

3

EBAG9 is a tumor-promoting and prognostic factor for bladder cancer.

Kumagai J, Urano T, Ogushi T, Takahashi S, Horie-Inoue K, Fujimura T, Azuma K, Muramatsu M, Ouchi Y, Kitamura T, Inoue S. Kumagai J, et al. Among authors: inoue s. Int J Cancer. 2009 Feb 15;124(4):799-805. doi: 10.1002/ijc.23982. Int J Cancer. 2009. PMID: 19030177 Free article.

4

ARFGAP3, an androgen target gene, promotes prostate cancer cell proliferation and migration.

Obinata D, Takayama K, Urano T, Murata T, Ikeda K, Horie-Inoue K, Ouchi Y, Takahashi S, Inoue S. Obinata D, et al. Among authors: inoue s. Int J Cancer. 2012 May 15;130(10):2240-8. doi: 10.1002/ijc.26224. Epub 2011 Sep 22. Int J Cancer. 2012. PMID: 21647875 Free article.

5

CtBP2 modulates the androgen receptor to promote prostate cancer progression.

Takayama K, Suzuki T, Fujimura T, Urano T, Takahashi S, Homma Y, Inoue S. Takayama K, et al. Among authors: inoue s. Cancer Res. 2014 Nov 15;74(22):6542-53. doi: 10.1158/0008-5472.CAN-14-1030. Epub 2014 Sep 16. Cancer Res. 2014. PMID: 25228652

6

Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.

Zheng Y, Ishiguro H, Ide H, Inoue S, Kashiwagi E, Kawahara T, Jalalizadeh M, Reis LO, Miyamoto H. Zheng Y, et al. Among authors: inoue s. Mol Endocrinol. 2015 Oct;29(10):1486-97. doi: 10.1210/me.2015-1128. Epub 2015 Aug 31. Mol Endocrinol. 2015. PMID: 26322830 Free PMC article.

7

Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.

Kawahara T, Ide H, Kashiwagi E, Patterson JD, Inoue S, Shareef HK, Aljarah AK, Zheng Y, Baras AS, Miyamoto H. Kawahara T, et al. Among authors: inoue s. Am J Cancer Res. 2015 Sep 15;5(10):2959-68. eCollection 2015. Am J Cancer Res. 2015. PMID: 26693052 Free PMC article.

8

Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.

Kawahara T, Aljarah AK, Shareef HK, Inoue S, Ide H, Patterson JD, Kashiwagi E, Han B, Li Y, Zheng Y, Miyamoto H. Kawahara T, et al. Among authors: inoue s. Prostate. 2016 Jun;76(8):744-56. doi: 10.1002/pros.23164. Epub 2016 Feb 11. Prostate. 2016. PMID: 26864615

9

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H. Kashiwagi E, et al. Among authors: inoue s. Oncotarget. 2016 Aug 2;7(31):49169-49179. doi: 10.18632/oncotarget.9994. Oncotarget. 2016. PMID: 27322140 Free PMC article.

10

ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion.

Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, Netto GJ, Ishiguro H, Miyamoto H. Kawahara T, et al. Among authors: inoue s. Oncotarget. 2016 Aug 16;7(33):53599-53610. doi: 10.18632/oncotarget.10679. Oncotarget. 2016. PMID: 27447553 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,797 results

Search Page